CCES – (Ottawa, Ontario – March 10, 2016) – The Canadian Centre for Ethics in Sport (CCES) announced today that Ana Laura Portuondo-Isasi, a judo athlete, received a sanction of two years for an anti-doping rule violation. The athlete’s urine sample, collected during in-competition doping control on May 17, 2015, revealed the presence of salbutamol in excess of the threshold stated in the World Anti-Doping Agency Prohibited List.
The presence of salbutamol, classified as a “specified substance” on the Prohibited List, is considered an adverse analytical finding when the urinary concentration exceeds 1,000ng/mL. Under the rules of the Canadian Anti-Doping Program (CADP), an athlete facing a first violation involving a “specified substance” can seek to have the sanction reduced. Based on CCES’ assessment of the athlete’s degree of fault, the CCES proposed a sanction period of two years.
In response to the CCES’ notification of the adverse analytical finding, Ms. Portuondo-Isasi acknowledged the anti-doping rule violation and a hearing was held to determine the sanction length. Arbitrator Patrice Brunet imposed a sanction of two years ineligibility from sport, terminating May 16, 2017. The athlete, who resides in La Prairie, Quebec, is ineligible to participate in any capacity with any sport signatory to the Canadian Anti-Doping Program (CADP), including training with teammates.
A copy of the full decision can be found at www.crdsc-sdrcc.ca.
The CCES is an independent, national, not-for profit organization with a responsibility to administer the CADP. Under the CADP rules, the CCES announces publicly every anti-doping rule violation. We recognize that true sport can make a great difference for individuals, communities and our country. We are committed to working collaboratively to activate a values-based and principle-driven sport system; protecting the integrity of sport from the negative forces of doping and other unethical threats; and advocating for sport that is fair, safe and open to everyone.
— 30 —
For further information, please contact:
+1 613-521-3340 x3314